Brief: FDA Grants Breakthrough Device Designation For Seastar Medical’s Selective Cytopheretic Device For Adults Undergoing Chronic Dialysis
06/11/2024 14:05
Nov 6 (Reuters) - SeaStar Medical Holding Corp ICU.O :
* FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION FOR SEASTAR
MEDICAL’S
SELECTIVE CYTOPHERETIC DEVICE FOR ADULTS UNDERGOING CHRONIC
DIALYSIS
Source text: ID:nGNX9ksmD7
Further company coverage: ICU.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview